Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of ...

Syndax (SNDX) announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral ...

Syndax (SNDX) delivered earnings and revenue surprises of 13.27% and 96.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Narrows FY24 total operating expenses view to $365M-$370M from $355M-$375M, which includes milestone payments that the Company expects to ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All participants have been placed in a listen-only mode. You'll have an ...

Analysts are estimating that Syndax Pharmaceuticals will report an earnings per share (EPS) of $-1.11. Investors in Syndax Pharmaceuticals are eagerly awaiting the company's announcement, hoping for ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...

The global leukemia therapeutics treatment market has seen considerable growth, progressing from USD 14,504.8 million in 2022 to USD 15,246.7 million in 2023. With a projected compound annual growth ...

Stifel 2024 Healthcare Conference in New York, NY with a fireside chat on Monday, November 18, 2024, at 1:50 p.m. ET A live webcast of the fireside chats will be available in the Investor section of ...

On Friday, Syndax Pharmaceuticals Inc (SNDX) stock saw a modest uptick, ending the day at $18.98 which represents a slight increase of $0.12 or 0.64% from the prior close of $18.86. The stock opened ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...